S100A6 and metabolic dysfunction-associated steatotic liver disease: As for S100A6, a member of the S100 family of calcium-binding proteins [53], has been reported to be associated with T2DM development, contributing to hepato-pancreatic communication to reduce insulin production and promote the progression of T2DM in individuals with nonalcoholic fatty liver disease [54].